Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
August 07 2019 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that Troy Wilson, Ph.D., J.D., President and Chief Executive
Officer, is scheduled to present at the 2019 Wedbush PacGrow
Healthcare Conference on Wednesday, August 14, 2019 at 12:45 p.m.
ET / 9:45 a.m. PT. The conference will be held August 13-14, 2019
in New York City.
A live audio webcast of the presentation will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. Kura’s pipeline consists of small molecule
drug candidates that target cancer signaling pathways where there
is a strong scientific and clinical rationale to improve outcomes
by identifying those patients most likely to benefit from
treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl
transferase inhibitor, for which Kura has initiated a
registration-directed trial in recurrent or metastatic patients
with HRAS mutant head and neck squamous cell carcinoma. In
addition, tipifarnib is being evaluated in multiple other Phase 2
clinical trials in solid tumor and hematologic indications. Kura’s
pipeline also includes KO-947, an ERK inhibitor, currently in a
Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor,
which has been cleared to begin a Phase 1 clinical trial. For
additional information about Kura, please visit the Company’s
website at www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024